TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03831945

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-1074
Description: 10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: 2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
Study: NCT04581057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific blood sampling
Description: A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α
Study: NCT00673075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Study: NCT01524094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
Description: Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)
Description: Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
Study: NCT00408031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
Study: NCT02071342

Intervention type: PROCEDURE
Intervention: angioplasty
Description: patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
Study: NCT01021553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK557296
Description: 50 mg GSK557296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK557296
Description: 150 mg GSK557296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01943019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study: NCT04175925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986322 Placebo
Description: Specified Dose on Specified Days
Study: NCT00972296

Intervention type: DEVICE
Intervention: Carbon fiber ankle foot orthosis versus cast boot
Description: Relief of ankle pain and normalizing of gait using either device.
Study: NCT02027428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane (Induction)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
Study: NCT04175925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986322 Placebo
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Specified Dose on Specified Days
Study: NCT02762747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preperitoneal suction drainage
Description: preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
Study: NCT03305380

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.

Intervention type: OTHER
Intervention: No interventions
Description: As this is a patient registry, there are no interventions.
Study: NCT01314560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample
Study: NCT01056601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Study: NCT04022018

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Description: CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no adaptive radiotherapy
Description: Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
Study: NCT03791853

Intervention type: DIAGNOSTIC_TEST
Intervention: Light-CT
Description: Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
Study: NCT02011347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05289011

Intervention type: OTHER
Intervention: Interviews and questionnaires
Description: * Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment
Study: NCT01492413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online lifestyle counseling and a fortified diet beverage
Description: The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online lifestyle counseling and a fortified diet beverage
Description: The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online lifestyle counseling and a fortified diet beverage
Description: The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online lifestyle counseling and a fortified diet beverage
Description: The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
Study: NCT01375387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 100 mg oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: 100 mg oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 2 X 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 2 X 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 4 X 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 4 X 100mg tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 3
Description: Placebo - 3 tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 3
Description: Placebo - 3 tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4
Description: Placebo - 4 tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4
Description: Placebo - 4 tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo - 2 tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: Placebo - 2 tablets
Study: NCT00862446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 1 gram/kg/day daily until on feeds
Study: NCT00829231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Mildly Hepatic Impaired Subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Moderately Hepatic Impaired Subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Healthy Subjects
Study: NCT00284661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAST FIX
Description: Fast fix repair of a meniscal tear

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal suturing
Description: standard suturing of meniscal tear
Study: NCT01401868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-143
Description: experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Study: NCT05366803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
Study: NCT03465241

Intervention type: DIAGNOSTIC_TEST
Intervention: the ctDNA dynamic monitoring
Description: To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
Study: NCT03072615

Intervention type: DIAGNOSTIC_TEST
Intervention: Stiffness measurement
Description: Transient Elastopgraphy (TE) or Shear-Wave-Elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Stiffness measurement
Description: Transient Elastopgraphy (TE) or Shear-Wave-Elastography
Study: NCT03572140

Intervention type: DIAGNOSTIC_TEST
Intervention: RAVS In relapsed and resistent cases
Description: assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen

Intervention type: DIAGNOSTIC_TEST
Intervention: RAVS In relapsed and resistent cases
Description: assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
Study: NCT01346839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact Intervention
Description: The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
Study: NCT01133054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: surgery or stenting
Study: NCT03653286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES and Run
Description: NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.

Intervention type: OTHER
Group type: OTHER
Intervention: Only Run
Description: RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
Study: NCT02696590

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
Study: NCT03289442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: patients were positioned on their supine position to receive colonoscopy insertion
Study: NCT02655315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone
Description: 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo twice daily morning and evening. The treatment lasts nine months
Study: NCT01315873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment.
Study: NCT03566563

Intervention type: OTHER
Intervention: Screening
Description: Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
Study: NCT00003958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT02027428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (Induction)
Description: 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane (Maintenance)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (Maintenance)
Description: The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents

Intervention type: DRUG
Group type: OTHER
Intervention: Abraxane (Induction)
Description: 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin (Induction)
Description: 6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (Maintenance)
Description: The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
Study: NCT06104943

Intervention type: OTHER
Intervention: Heredity for cardiovascular disease
Description: First degree relatives with a diagnosis of Cardiovascular disease.

Intervention type: OTHER
Intervention: Heredity for pancreatitis
Description: First degree relatives with a diagnosis of pancreatitis.

Intervention type: OTHER
Intervention: Heredity for type 2 diabetes
Description: First degree relatives with a diagnosis of type 2 diabetes.

Intervention type: OTHER
Intervention: Heredity for hypertriglyceridemia
Description: First degree relatives with hypertriglyceridemia
Study: NCT04860180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenalectomy
Study: NCT04352725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume measurement and incremental PEEP titration
Description: * End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o
Study: NCT02871492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir 5% w/w ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pritelivir ointment matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zovirax® cream
Study: NCT03847857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Porcine Fibrin Sealant (PFS)
Description: McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: McKeown esophagectomy
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McKeown esophagectomy
Description: McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.